Sanara MedTech Inc.

BioWound Solutions, LLCMedical DeviceUnited States

71% match

BioWound Solutions, LLC provides advanced wound management products and dressings, including collagen technologies, antimicrobial protections, and moisture-balancing solutions. The company serves healthcare providers, clinicians, and organizations by supplying medical products designed to promote wound healing and clinical efficiency.

RenovoDerm, LLCMedical Device & BiotechnologyUnited States

70% matchPrivate

RenovoDerm manufactures advanced wound care products, specifically the Phoenix Wound Matrix, which is a synthetic, bioabsorbable scaffold designed to promote tissue regeneration and healing for acute and chronic wounds and burns. The company serves medical specialists such as podiatric surgeons and wound care providers by offering solutions to improve patient healing outcomes.

Clyra Medical Technologies, Inc.Medical DevicesUnited States

69% matchPrivate

Clyra Medical Technologies, Inc. develops advanced wound management and irrigation products utilizing patent-protected oxidative chemistry. The company serves patients and healthcare providers by offering safe, non-toxic treatments designed to combat microorganisms and aid in wound healing without harming healthy tissue.

Debx, LLCMedical DeviceUnited States

68% matchPrivate

DEBx Medical develops and provides wound care products, specifically its flagship product Debrichem, designed to eliminate biofilm and infection in chronic and complex wounds. The treatment is used by healthcare professionals in ambulatory and hospital settings to facilitate faster wound bed preparation and healing while reducing the need for antibiotics and complex surgeries.

MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.

Covalon Technologies Ltd., a Canadian company based in Mississauga, innovates, develops, manufactures, and commercializes medical technologies and products globally. Its operations span major international markets, including North America, Europe, the Middle East, Asia, and Latin America, with licensing agreements in place. The company leverages three distinct proprietary technology platforms. Firstly, its collagen matrix platform underpins a family of products aimed at treating a variety of chronic and infected wounds, such as diabetic, pressure, and venous ulcers, as well as donor and graft sites, traumatic injuries healing by secondary intention, dehisced surgical wounds, and first- and second-degree burns. Secondly, an antimicrobial silicone adhesive platform is incorporated into pre- and post-surgical and vascular access products; these are specifically engineered to provide broad-spectrum antimicrobial protection by eliminating bacteria or yeast on contact. Thirdly, a unique medical coating platform employs a proprietary photo-polymerization process to generate active grafting sites, enabling the initiation and growth of new polymer chains directly on existing medical devices. Covalon's product portfolio, branded under "Covalon," encompasses advanced wound care dressings, surgical and peri-operative solutions, and infection management tools. These offerings reach a diverse clientele, including hospitals, specialized wound and burn centers, acute and long-term care facilities, home health care agencies, and physicians' offices, via a combination of direct sales and extensive third-party distribution networks.